An observational study in Retinal Vein Occlusion, sponsored by Renmin Hospital of Wuhan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.
Sponsored by Renmin Hospital of Wuhan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Retinal Vein Occlusion with a site in China — 8 open to participants now, 12 under way, 1 of them phase 3. Retinal Vein Occlusion · China.
Among the 37 studies in Retinal Vein Occlusion with a site in China, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2019, is one of 11 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 13th registered.
291 studies on the registry are indexed under Retinal Vein Occlusion; 33 are open to participants now.
Browse Retinal Vein Occlusion studies →8 of the 37 studies in Retinal Vein Occlusion with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–80
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50+
Renmin Hospital of Wuhan University · Sites in China
Ages 18+
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 19 Retinal Vein Occlusion studies recruiting now, 14 (74%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 11 · Phase 4 3
First in 2011; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 180 across 71 observational studies indexed under Retinal Vein Occlusion.
Median enrollment 135 across the 26 interventional studies, 1,000 across the 11 observational. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
Renmin Hospital of Wuhan University is the lead sponsor of 86 studies on the registry; 29 are open to participants now.
Renmin Hospital of Wuhan University has 2 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
2 of the studies in Retinal Vein Occlusion with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07201415Zhongnan HospitalMinimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma | 2026-12-31 |
| NCT07133438First Affiliated Hospital of Chongqing Medical UniversityMecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Retinal Vein Occlusion with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The changes of ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion by ultra-wide field fluorescence angiography (UWFA)
In this study, the ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion will be evaluated by ultra-wide field fluorescence angiography (UWFA). UWFA has a wider range than conventional angiography, and can clearly observe the peripheral retina. The purpose of this study is to quantitatively analyze these changes and investigate the effect on macular edema and neovascularization secondary to retinal vein occlusion.
Chinese
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change in non-perfused areas in different retinal area
Change in non-perfused areas in different retinal area from Baseline to 1,2,3,6,9and 12 months
Time frame: Baseline and1,2,3,6,9and 12 months
Change in best corrected visual acuity
Change in best corrected visual acuity from Baseline to 1,2,3,6,9and 12 months
Time frame: Baseline and1,2, 3, 6, 9 and 12 months
Change in central macular thickness
Change in central macular thickness from Baseline to 1,2,3,6,9and 12 months
Time frame: Baseline and1,2, 3, 6, 9 and 12 months
Started Sep 2019 (actual). Primary completion is estimated for Dec 2024, 62 months after the start.
Of 26 observational studies under Retinal Vein Occlusion, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 69. This study's planned 62 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renmin Hospital of Wuhan University